Articaine hydrochloride; epinephrine bitartrate - Generic Drug Details

What are the generic sources for articaine hydrochloride; epinephrine bitartrate and what is the scope of patent protection?

Articaine hydrochloride; epinephrine bitartrate is the generic ingredient in five branded drugs marketed by Hospira, Pierrel, Deproco, and Hansamed Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Eleven suppliers are listed for this compound.

Summary for articaine hydrochloride; epinephrine bitartrate

US Patents:	0
Tradenames:	5
Applicants:	4
NDAs:	5
Finished Product Suppliers / Packagers:	11
DailyMed Link:	articaine hydrochloride; epinephrine bitartrate at DailyMed

Pharmacology for articaine hydrochloride; epinephrine bitartrate

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

Anatomical Therapeutic Chemical (ATC) Classes for articaine hydrochloride; epinephrine bitartrate

A01AD	Other agents for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

B02BC	Local hemostatics
B02B	VITAMIN K AND OTHER HEMOSTATICS
B02	ANTIHEMORRHAGICS
B	Blood and blood forming organs

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

N01BB	Amides
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03AA	Alpha- and beta-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for articaine hydrochloride; epinephrine bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-002	Feb 26, 2010		RX	Yes	Yes
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-001	Feb 26, 2010		RX	Yes	No
Hansamed Inc	ULTACAN FORTE	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	201750-001	Jul 11, 2017		DISCN	No	No

Market Dynamics and Financial Trajectory for Articaine Hydrochloride with Epinephrine Bitartrate

Last updated: February 20, 2026

What is the current market landscape for articaine hydrochloride with epinephrine bitartrate?

Articaine hydrochloride with epinephrine bitartrate is a local anesthetic primarily used in dentistry. It is marketed globally under various brand names, with the most prominent being Septocaine by Septodont. The drug gained approval in the late 20th century and has since established a strong presence in dental anesthesia supply markets. The demand is driven by increasing dental procedures worldwide, coupled with rising oral health awareness.

The global dental anesthetic market was valued at approximately USD 1.2 billion in 2020, with articaine products accounting for about 40–45% of this segment. Regional demand drivers include North America, Europe, and parts of Asia-Pacific. North America dominates the market, capturing over 45% of sales volume, attributed to high dental care utilization and advanced healthcare infrastructure. Europe follows, with consistent growth driven by aging populations requiring more dental interventions. Asia-Pacific exhibits rapid growth, driven by expanding dental clinics and increasing oral health awareness.

How does regulatory environment influence market potential?

Regulatory frameworks for local anesthetics vary by country. The FDA approved articaine in the United States in 2000, with indications including infiltration and nerve block anesthesia. European countries, under the EMA, authorized its use mainly after safety and efficacy evaluations, often aligning with FDA standards. Regulatory approvals facilitate market access but involve substantial compliance costs.

In China and India, regulatory pathways are often less rigorous but are evolving with increased safety standards. The approval process affects market entry timelines and costs for manufacturers. Variations in regulations impact the pace at which new formulations or combined products, such as those incorporating epinephrine, can enter local markets.

What are the competitive dynamics among major players?

Market players include Septodont, DENTSPLY Sirona, and Anaest I.C., among others. Septodont holds a significant share, owing to its early market entry and extensive distribution network. DENTSPLY offers a broad portfolio of dental anesthetics, including formulations with articaine and epinephrine.

Innovation in formulation, such as longer-lasting or low-dose options, influences competition. Companies investing in research are developing new combinations or delivery systems. Patents associated with specific delivery mechanisms or formulations impact market exclusivity periods.

What technological and product advancements are shaping future growth?

Advancements include sustained-release formulations and novel delivery systems like liposomal carriers. These aim to prolong anesthesia duration and reduce dosage frequency. Innovations in combination products with adjuncts such as vasoconstrictors, including epinephrine, seek to optimize efficacy and safety.

Advances in digital dentistry, including computer-controlled local anesthetic delivery, could alter market dynamics by improving precision and patient comfort. Additionally, development of needleless or topical formulations may expand market reach beyond traditional dental clinics.

How do pricing, reimbursement policies, and market access affect financial projections?

Pricing varies globally. In North America, the average wholesale price (AWP) of articaine with epinephrine ranges from USD 10 to USD 20 per cartridge. Reimbursement policies generally favor dental health procedures, supporting sales volumes but exerting pressure on manufacturer margins.

In cost-sensitive markets like India and parts of Southeast Asia, price competition leads to lower margins, impacting profitability. Patent expirations or the absence of patent protection for certain formulations could enable generic manufacturers, increasing market competition and driving prices down.

What forecasts can be made about the financial trajectory over the next five years?

Global sales of articaine-based anesthetics are projected to grow at a compound annual growth rate (CAGR) of 5–7% between 2023 and 2028. Growth drivers include increased dental procedures, technological adoption, and expanding markets in Asia-Pacific.

Despite regulatory challenges, established players are expected to maintain leadership through ongoing product innovation. Market penetration is likely to deepen in emerging economies, supported by rising disposable incomes and healthcare investments.

Patent expiration timelines could introduce generics, potentially reducing prices but expanding volume. Continued innovation and strategic partnerships are essential for sustained profit margins.

Aspect	Key Data	Source
Global dental anesthetic market	USD 1.2 billion (2020)	[1]
Articaine market share within dental anesthetics	40–45%	[2]
North America market share	>45%	[3]
CAGR forecast (2023–2028)	5–7%	[4]

Key Takeaways

• The market for articaine hydrochloride with epinephrine bitartrate is influenced by rising global dental procedures, technological innovation, and regulatory environments.
• North America and Europe dominate sales, but Asia-Pacific exhibits rapid growth opportunities.
• Competitive advantage depends on formulation innovation, distribution reach, and patent status.
• Pricing pressures and reimbursement policies affect margins; future growth hinges on market expansion and product differentiation.
• Patent expirations could introduce price competition but also broaden access and volume sales.

FAQs

1. What factors are driving growth in markets outside North America and Europe?
Growing dental infrastructure, rising oral health awareness, and increasing disposable incomes are expanding demand in Asia-Pacific, Latin America, and parts of Africa.

2. How significant is patent expiry for articaine formulations?
Patent expirations can lead to generic entry, reducing prices and profit margins but increasing market volume. Expiration dates vary by jurisdiction but typically occur 10–15 years post-approval.

3. Are there emerging formulations that threaten current market leaders?
Yes. Sustained-release formulations and needleless delivery systems are under development, offering potential alternatives to traditional injections.

4. How do reimbursement policies differ globally?
Reimbursements are well-established in North America and Europe, supporting sales. In emerging markets, reimbursement schemes are less common, making cost a critical factor.

5. What are the regulatory hurdles for new formulations combining epinephrine?
Developing combination products requires demonstrating safety and efficacy. Regulatory approval timelines depend on regional agencies' requirements, with some jurisdictions requiring extensive clinical data.

---

Sources

1. Markets and Markets. (2020). Dental Market Growth Analysis. https://www.marketsandmarkets.com.
2. Septodont. (2022). Product Portfolio. https://septodont.com.
3. DENTSPLY Sirona Annual Report. (2021). Financial Highlights. https://dentalsystems.dentsplysirona.com.
4. Research and Markets. (2021). Dental Anesthetics Market Forecast. https://researchandmarkets.com.